DINURU

The Synthesis and Evaluation of Organometallic Dinuclear Ruthenium Complexes as Anti-Cancer Drugs

Coordinatore	ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE    more  Organization address address: BATIMENT CE 3316 STATION 1 city: LAUSANNE postcode: 1015 contact info Titolo: Prof. Nome: Paul Joseph Cognome: Dyson Email: send email Telefono: +41 21 693 98 54 Fax: +41 21 693 97 80
Nazionalità Coordinatore	Switzerland [CH]
Totale costo	178˙601 €
EC contributo	178˙601 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2010-IEF
Funding Scheme	MC-IEF
Anno di inizio	2011
Periodo (anno-mese-giorno)	2011-07-01   -   2013-06-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE  Organization address address: BATIMENT CE 3316 STATION 1 city: LAUSANNE postcode: 1015 contact info Titolo: Prof. Nome: Paul Joseph Cognome: Dyson Email: send email Telefono: +41 21 693 98 54 Fax: +41 21 693 97 80	CH (LAUSANNE)	coordinator	178˙601.60

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Current platinum-based anti-cancer drugs, such as cisplatin, are well established in the successful treatment of various forms of cancer, however, the use of these drugs is significantly limited by associated side effects and drug resistance. Ruthenium-based alternatives, some of which are in clinical testing, have shown considerable promise, exhibiting low general toxicity alongside selectivity and high activity toward cancerous tissue.

This proposal takes advantage of these remarkable properties in the design, synthesis and evaluation of novel dinuclear ruthenium-based anti-cancer drugs. These complexes will contain two ruthenium moieties linked by an organic tether – the structure of which will have a major influence on the conformation of the complexes and will therefore influence their interactions with biomolecular targets. The relationship between complex structures and their anti-cancer properties will be studied and their biomolecular targets identified, allowing the rational development of more potent anti-cancer drugs that express their activity by non-DNA damaging modes of action – essential in overcoming the toxicity and resistance problems of established metal complexes.

To achieve these objectives the candidate will build upon his experience in synthetic and analytical chemistry to isolate and characterize the complexes; he will develop expertise in bio-analytical techniques to allow him to identify their biomolecular targets and evaluate complex-biomolecule interactions/reactivity to probe their biological mode of anti-cancer activity.

Through this project the candidate will gain substantial new expertise in biochemistry, proteomics and advanced mass spectrometry. He will gain experience in the management and coordination of an independent project whilst developing scientific and complementary skills, such as leadership qualities and teaching skills - essential in his development as a promising independent researcher.'